Automated insulin delivery ups time in target glucose range in type 1 diabetes.
Among patients with type 1 diabetes, percentage of time in the target glucose range is increased with the use of an open-source automated insulin delivery (AID) system, according to a study published in the Sept. 8 issue of the New England Journal of Medicine.
Automated insulin delivery systems are automated (or semi-automated) systems designed to assist people with diabetes, primarily type 1, by automatically adjusting insulin delivery to help them control their blood glucose levels.
Open-source automated insulin delivery (AID) systems are used by many patients with type 1 diabetes. Data are needed on the efficacy and safety of an open-source AID system.
Mercedes J. Burnside, M.B., Ch.B., from the University of Otago in New Zealand, and colleagues conducted a multicenter, open-label trial involving 97 patients (48 children and 49 adults) with type 1 diabetes who were randomly assigned to use an open-source AID system or a sensor-augmented insulin pump (44 and 53 patients, respectively).
The researchers found that the mean time in the target range increased in the AID group (61.2 ± 12.3 to 71.2 ± 12.1 percent) and decreased in the control group (57.7 ± 14.3 to 54.5 ± 16.0 percent) at 24 weeks (adjusted difference, 14 percentage points), with no treatment effect based on age. Compared with those in the control group, patients in the AID group spent 3 hours 21 minutes more in the target glucose range (70 to 180 mg/dL) per day. Neither group experienced severe hypoglycemia or diabetic ketoacidosis. Owing to connectivity issues, two patients in the AID group withdrew from the trial.
“Patients in the AID group had improved glycemic control while maintaining a low percentage of time during which the glucose level was less than 70 mg per deciliter,”the authors write.
More information: Mercedes J. Burnside et al, Open-Source Automated Insulin Delivery in Type 1 Diabetes, New England Journal of Medicine (2022). DOI: 10.1056/NEJMoa2203913
Sue A. Brown, On the Path toward Expanding Treatment Options for Diabetes, New England Journal of Medicine (2022). DOI: 10.1056/NEJMe2209840
Journal information: New England Journal of Medicine